Helal, Gouda K <br/><br/>
Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.  [electronic resource] 

 -  European journal of gastroenterology & hepatology  May 2016 
 - 553-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1473-5687 
<br/><br/><label>Standard No.: </label>10.1097/MEG.0000000000000587  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--adverse effects<br/>Drug Therapy, Combination<br/>Egypt<br/>Ezetimibe--adverse effects<br/>Female<br/>Hepacivirus--drug effects<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Interferon-alpha--adverse effects<br/>Male<br/>Middle Aged<br/>Obesity--complications<br/>Polyethylene Glycols--adverse effects<br/>Prospective Studies<br/>Recombinant Proteins--adverse effects<br/>Ribavirin--adverse effects<br/>Single-Blind Method<br/>Time Factors<br/>Treatment Outcome<br/>Viral Load<br/>Virus Internalization--drug effects